<DOC>
	<DOCNO>NCT00359892</DOCNO>
	<brief_summary>Defects apoptotic process lead onset cancer allow cell grow unchecked oncogenic signal present . Obatoclax design restore apoptosis inhibition Bcl-2 family protein , thereby reinstate natural process cell death often inhibited cancer cell . This multi-center , open-label , Phase II study single-agent obatoclax administer 2-week cycle 24-hour infusion every 2 week fix dose 60 mg patient relapse refractory Hodgkin 's Lymphoma . Infusions may administer out-patient basis . No investigational commercial agent therapy describe protocol may administer intent treat patient 's malignancy . Supportive care measure include direct control symptom result Hodgkin 's Lymphoma ( blood product , growth factor , etc . ) allow .</brief_summary>
	<brief_title>Safety Efficacy Obatoclax Mesylate ( GX15-070MS ) Treatment Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Pathological confirmation Hodgkin 's Lymphoma . Must measurable disease . Evidence progressive disease follow least one prior line combination therapy . Must fail , refuse , otherwise candidate stem cell transplant . Patient 's must normal organ function . Willing submit blood sampling plan PK PD analyse . Ability understand willingness sign write informed consent form . No agent therapy administer intent treat malignancy . Patients prior exposure obatoclax . Prior allogeneic stem cell transplant evidence graft versus host disease , requirement steroid immunosuppressive therapy . Uncontrolled , intercurrent illness . Pregnant woman woman breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>